Trasylol Caused Injuries When Cheaper Alternatives Were Available
The risks associated with Trasylol --- kidney failure, serious heart problems and possibly death --- long ago could have been avoided if Bayer and the FDA would have heeded the warnings revealed in several studies. Why was Trasylol the drug of choice for controlling bleeding during surgery when cheaper alternatives were available? Recent studies state that the cost per dose of Trasylol is $1,300. The generic drug Amicar, which also limits bleeding in operations, is $11 per dose. The generic Cyklokapron, another option, is $44 per dose. According to the studies, neither of the generic drugs was linked to increased risk of kidney failure, heart attack or stroke. What is the reason for exposing the American public to increased risk at a high cost when cheaper and safer options are available?#